Takeaways: Mint’s expanded partnership with Bayer strengthens its position as a Canadian pharmaceutical distribution partner, broadening its footprint across cardiovascular and women’s health. T...
Takeaways: The approval of Nduvra (tapinarof) 1% for moderate to severe atopic dermatitis gives Organon a first‑in‑class, steroid‑free topical that can be prescribed by family physicians w...
Pfizer and BioNTech Receive Health Canada Authorization for XFG-Adapted Comirnaty Pfizer and BioNTech received Health Canada authorization for their XFG variant-adapted Comirnaty COVID-19 vaccine for ...
Takeaways: The Canadian approval expands Epkinly into a second major lymphoma indication (after DLBCL), giving AbbVie a bispecific‑based triplet option in relapsed/refractory follicular ly...
Abbott’s Volt PFA System Debuts in Canada Abbott announced the first Canadian use of its Volt Pulsed Field Ablation (PFA) System at McGill University Health Centre in Montreal to treat patients with a...
Takeaways: Health Canada’s authorization of the XFG‑adapted Comirnaty vaccine for the 2026–2027 season keeps Pfizer/BioNTech aligned with national recommendations to match contemporary Omicron l...
Takeaways: Health Canada’s acceptance of Knight Therapeutics’ New Drug Submission for Gemtesa (vibegron) moves the therapy closer to potential approval in Canada for adults with overactive bladd...
Minjuvi Gains Accelerated Funding in Ontario for Relapsed/Refractory Follicular Lymphoma Incyte announced that Minjuvi (tafasitamab), in combination with R² (lenalidomide and rituximab), is now funded...
Takeaways: Siliq’s listing under Alberta’s public drug plan expands brodalumab’s public coverage across Canada, leaving only British Columbia without provincial reimbursement and improving...
Leqembi Receives Positive Public Reimbursement Recommendation in Canada BioArctic announced that CDA-AMC has issued a final recommendation supporting public reimbursement of Leqembi (lecanemab) for el...
